ревматоидный артрит, базисные противовоспалительные препараты, генно-инженерные биологические препараты, ингибиторы тирозинкиназы, тофаци-тиниб, rheumatoid arthritis, disease-modifying anti-inflammatory drugs, genetically engineered biologic drugs, tyrosine kinase inhibitors, tofacitinib, Medicine

The article tells about the applicability of tyrosine kinase inhibitors in the treatment of rheumatoid arthritis (RA). The first drug from the new subgroup of targeted disease-modifying synthetic anti-inflammatory drugs is in focus - the oral inhibitor of Janus kinase Tofacitinib. There are results of ORAL START, ORAL SOLO and ORAL STEP studies which evaluated tofacitinib in three categories of patients: those who didn't undergo methotrexate (MTX) treatment in the past; patients without response to MT and other disease modifying anti-rheumatic drugs (DMARDs); patients with insufficient response to TNF-alpha inhibitors. The results show that Tofacitinib can be indicated either after failure of DMARD therapy and genetically engineered biologic drugs, or can be used as first-line therapy in RA. According to the author, Tofacitinib is a very promising medication which can become an essential element of the active treatment strategy for RA patients to achieve clinical remission. Nevertheless, further research is needed, as well as records of practical outcomes of the drug use.